Tin tức & Cập nhật
Xem bài viết Bệnh nhiễm khuẩn
Xem

More syphilis cases picked up with universal vs targeted ED screening
Relying on targeted screening models for syphilis in emergency departments (EDs) leaves a substantial number of active cases undetected, new research shows.
More syphilis cases picked up with universal vs targeted ED screening
24 Mar 2025
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
23 Mar 2025
Ensitrelvir safe, effective in preventing COVID-19 in households
Treatment with ensitrelvir among household contacts (HHC) of index patients (IP) with COVID-19 within 72 h after the onset of IP symptoms demonstrates efficacy and an acceptable safety profile as postexposure prophylaxis (PEP) in SCORPIO-PEP, a phase III placebo-controlled trial.
Ensitrelvir safe, effective in preventing COVID-19 in households
21 Mar 2025
First HIV cure trial affirms tolerability of investigational combo in women with HIV
A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.
First HIV cure trial affirms tolerability of investigational combo in women with HIV
21 Mar 2025
Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV
Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.




